<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584777</url>
  </required_header>
  <id_info>
    <org_study_id>381401</org_study_id>
    <nct_id>NCT02584777</nct_id>
  </id_info>
  <brief_title>A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis</brief_title>
  <official_title>A Phase II, Prospective, Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Asian Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post- Essential Thrombocythemia Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of&#xD;
      pacritinib in Asian subjects with myelofibrosis (MF), which includes primary MF (PMF),&#xD;
      post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving a ≥35% reduction in spleen volume</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Measured by MRI or CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥50% reduction in total symptom score (TSS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) TSS 2.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with baseline platelet count &lt;100,000/μL achieving ≥35% reduction in spleen volume</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Measured by MRI or CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with baseline platelet count &lt;100,000/μL achieving ≥50% reduction in total symptom score (TSS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with baseline platelet count &lt;50,000/μL achieving ≥35% reduction in spleen volume</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Measured by MRI or CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with baseline platelet count &lt;50,000/μL achieving ≥50% reduction in total symptom score (TSS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in laboratory results</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in electrocardiograms (ECGs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: maximum observed concentration (Cmax)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: Time of maximum observed concentration (Tmax)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: minimum observed concentration (Cmin)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: area under the concentration curve (AUC)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: apparent volume of distribution (V/F)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter: Maximum observed effect (Emax)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter: time of maximum observed effect (tEmax)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter: area under the effect curve (AUEC)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Pacritinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pacritinib</intervention_name>
    <description>QD (Once a day)</description>
    <arm_group_label>Pacritinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Intermediate-1, intermediate-2, or high-risk PMF, PPV-MF or PET-MF as based on The&#xD;
             Dynamic International Prognostic Scoring System (DIPSS) criteria&#xD;
&#xD;
          2. Palpable splenomegaly ≥5 cm below the LCM in midclavicular line by physical&#xD;
             examination&#xD;
&#xD;
          3. TSS ≥13 on the MPN-SAF TSS 2.0, not including the inactivity question, based on a&#xD;
             single assessment during screening visit&#xD;
&#xD;
          4. Age ≥18 years old at the time of screening (or minimum age of legal consent consistent&#xD;
             with local regulations, if minimum is &gt;18 years of age)&#xD;
&#xD;
          5. ECOG performance status 0 to 3&#xD;
&#xD;
          6. Peripheral blast count &lt;10%&#xD;
&#xD;
          7. Absolute neutrophil count &gt;500/μL&#xD;
&#xD;
          8. Participants who are platelet or RBC transfusion dependent are eligible&#xD;
&#xD;
          9. Adequate liver and renal function, defined by liver transaminases (AST/serum glutamic&#xD;
             oxaloacetic transaminase [SOOT] and alanine aminotransferase [ALT]/serum glutamic&#xD;
             pyruvic transaminase [SGPT]) ≤3 × upper limit of normal ([ULN], AST/ALT ≤5 × ULN if&#xD;
             transaminase elevation is related to MF), direct bilirubin ≤4 × ULN, and creatinine&#xD;
             ≤2.5 mg/dL&#xD;
&#xD;
         10. At least 6 months from prior splenic irradiation&#xD;
&#xD;
         11. At least 12 months from prior 32P therapy&#xD;
&#xD;
         12. At least 1 week since prior treatment (most recent dose) with a potent CYP3A4&#xD;
             inhibitor or inducer&#xD;
&#xD;
         13. At least 4 weeks since any experimental treatment for PMF, PPV-MF, or PET-MF&#xD;
&#xD;
         14. At least 2 weeks since any treatment for PMF, PPV-MF, or PET-MF&#xD;
&#xD;
         15. If fertile, both males and females must agree to use effective birth control.&#xD;
&#xD;
         16. Able to understand and willing to complete symptom assessments using a&#xD;
             patient-reported outcomes instrument and comply with treatment and study procedures of&#xD;
             the protocol&#xD;
&#xD;
         17. Able to understand and willing to sign the informed consent form (ICF)&#xD;
&#xD;
         18. Participant is willing and able to comply with the requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any GI or metabolic condition that could interfere with absorption of oral medication&#xD;
&#xD;
          2. Life expectancy &lt;6 months&#xD;
&#xD;
          3. Prior treatment with a JAK2 inhibitor&#xD;
&#xD;
          4. Completed ASCT, or are eligible for and willing to complete ASCT&#xD;
&#xD;
          5. History of splenectomy or planning to undergo splenectomy&#xD;
&#xD;
          6. Uncontrolled intercurrent illness, including but not limited to ongoing active&#xD;
             infection, or psychiatric illness, or social situation that, in the judgment of the&#xD;
             treating physician, would limit compliance with study requirements&#xD;
&#xD;
          7. Other malignancy within the last 3 years, other than curatively treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, organ confined, or treated&#xD;
             non-metastatic prostate cancer with negative prostate specific antigen, in situ breast&#xD;
             carcinoma after complete surgical resection, or superficial transitional cell bladder&#xD;
             carcinoma&#xD;
&#xD;
          8. Inflammatory or chronic functional bowel disorder, such as Crohn's disease,&#xD;
             inflammatory bowel disease, chronic diarrhea, or constipation&#xD;
&#xD;
          9. Clinically symptomatic and uncontrolled cardiovascular disease&#xD;
&#xD;
         10. History of any of the following within 6 months prior to first dose of pacritinib:&#xD;
             myocardial infarction, severe/unstable angina, or symptomatic congestive heart failure&#xD;
&#xD;
         11. New York Heart Association Class II, III, or IV congestive heart failure&#xD;
&#xD;
         12. Participants with NCI CTCAE (version 4.03) Grade 2 cardiac arrhythmias may be&#xD;
             considered for inclusion, with the approval of the medical monitor, if the arrhythmias&#xD;
             are stable, asymptomatic and unlikely to affect participant safety. Participants will&#xD;
             be excluded if they have ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥3, QTc&#xD;
             prolongation &gt;450 ms, or other conditions that increase the risk for QT interval&#xD;
             prolongation (eg, heart failure, hypokalemia [defined as serum potassium &lt;3.0 mEq/L&#xD;
             that is persistent and refractory to correction], or family history of long QT&#xD;
             interval syndrome)&#xD;
&#xD;
         13. Erythropoietic agent within 28 days prior to first dose of pacritinib&#xD;
&#xD;
         14. Thrombopoietic agent within 14 days prior to first dose of pacritinib&#xD;
&#xD;
         15. Known seropositivity for human immunodeficiency virus or syphilis, or known active&#xD;
             hepatitis A, B or C virus infection&#xD;
&#xD;
         16. Participant has participated in another clinical study involving an IP or&#xD;
             investigational device within 30 days prior to enrollment or is scheduled to&#xD;
             participate in another clinical study involving an IP or investigational device during&#xD;
             the course of this study&#xD;
&#xD;
         17. Participant is a family member or employee of the investigator&#xD;
&#xD;
         18. If female, participant is pregnant or breastfeeding at the time of enrollment. Even if&#xD;
             breastfeeding can be discontinued, the participant should not be enrolled in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-essential thrombocythemia myelofibrosis</keyword>
  <keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

